Skip to main content
SpringerLink
Log in

Pyruvate Kinase M2: A Metabolic Tuner

  • Chapter
Tumor Cell Metabolism

Abstract

Metabolic enzymes are emerging as key mediators in modifying cell metabolism in response to extracellular signals, such as growth factors which trigger the upregulation of a specific isoform of pyruvate kinase (PK) M2. PKM2 alters its own catalytic activity by many different ways, and one of these involves the switch in the degree of oligomerization, shifting resting cell metabolism to a pro-proliferative one. A shift of enzymatic activity from high to low is generally considered as a trigger for cell division; however, such a change is guided under a delicate equilibrium, which if lost leads to uncontrolled cell metabolism, a reason for which PKM2 is associated with cancer and Warburg effect. Thus, a curiosity is aroused to understand the factors regulating PKM2 activity and expression and how these are affected by different metabolites and proteins. In this chapter, we discuss different levels of regulating PK expression and activity and possible therapeutic approaches, where PKM2 is proposed as a potential target for cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

PK:

Pyruvate kinase

PKM2:

Pyruvate kinase M2 isozyme

References

  • Ahmed AS, Dew T, Lawton FG, Papadopoulos AJ, Devaja O, Raju KS, Sherwood RA (2007) M2-PK as a novel marker in ovarian cancer. A prospective cohort study. Eur J Gynaecol Oncol 28:83–88

    CAS  PubMed  Google Scholar 

  • Akhtar K, Gupta V, Koul A, Alam N, Bhat R, Bamezai RN (2009) Differential behavior of missense mutations in the intersubunit contact domain of the human pyruvate kinase M2 isozyme. J Biol Chem 284:11971–11981

    PubMed Central  CAS  PubMed  Google Scholar 

  • Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M, Bellinger G, Sasaki AT, Locasale JW, Auld DS, Thomas CJ, Vander Heiden MG, Cantley LC (2011) Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334:1278–1283

    PubMed Central  CAS  PubMed  Google Scholar 

  • Anitha M, Kaur G, Baquer NZ, Bamezai R (2004) Dominant negative effect of novel mutations in pyruvate kinase-M2. DNA Cell Biol 23:442–449

    CAS  PubMed  Google Scholar 

  • Bluemlein K, Gruning NM, Feichtinger RG, Lehrach H, Kofler B, Ralser M (2010) No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2:393–400

    Google Scholar 

  • Bluemlein K, Gruning NM, Feichtinger RG, Lehrach H, Kofler B, Ralser M (2011) No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2:393–400

    PubMed Central  PubMed  Google Scholar 

  • Boxer MB, Jiang JK, Vander Heiden MG, Shen M, Skoumbourdis AP, Southall N, Veith H, Leister W, Austin CP, Park HW, Inglese J, Cantley LC, Auld DS, Thomas CJ (2010) Evaluation of substituted N, N’-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. J Med Chem 53:1048–1055

    PubMed Central  CAS  PubMed  Google Scholar 

  • Brinck U, Eigenbrodt E, Oehmke M, Mazurek S, Fischer G (1994) L- and M2-pyruvate kinase expression in renal cell carcinomas and their metastases. Virchows Arch 424:177–185

    CAS  PubMed  Google Scholar 

  • Chang CH, Curtis JD, Maggi LB, Faubert B, Villarino AV, O’sullivan D, Huang SC, Van Der Windt GJ, Blagih J, Qiu J, Weber JD, Pearce EJ, Jones RG, Earce EL (2013) Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153:1239–1251

    PubMed Central  CAS  PubMed  Google Scholar 

  • Chen J, Xie J, Jiang Z, Wang B, Wang Y, Hu X (2011) Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene 42:4297–4306

    Google Scholar 

  • Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC (2008a) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452:230–233

    CAS  PubMed  Google Scholar 

  • Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC (2008b) Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452:181–186

    CAS  PubMed  Google Scholar 

  • Cortes-Cros M, Hemmerlin C, Ferretti S, Zhang J, Gounarides JS, Yin H, Muller A, Haberkorn A, Chene P, Sellers WR, Hofmann F (2013) M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proc Natl Acad Sci USA 110:489–494

    PubMed Central  CAS  PubMed  Google Scholar 

  • David CJ, Chen M, Assanah M, Canoll P, Manley JL (2010) HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463:364–368

    PubMed Central  CAS  PubMed  Google Scholar 

  • Desmaret S, Qian L, Vanloo B, Meerschaert K, Van Damme J, Grooten J, Vandekerckhove J, Prestwich GD, Gettemans J (2005) Lysophosphatidic acid affinity chromatography reveals pyruvate kinase as a specific LPA-binding protein. Biol Chem 386:1137–1147

    CAS  PubMed  Google Scholar 

  • Dombrauckas JD, Santarsiero BD, Mesecar AD (2005) Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 44:9417–9429

    CAS  PubMed  Google Scholar 

  • Duan HF, Hu XW, Chen JL, Gao LH, Xi YY, Lu Y, Li JF, Zhao SR, Xu JJ, Chen HP, Chen W, Wu CT (2007) Antitumor activities of TEM8-Fc: an engineered antibody-like molecule targeting tumor endothelial marker 8. J Natl Cancer Inst 99:1551–1555

    CAS  PubMed  Google Scholar 

  • Eigenbrodt E, Gerbracht U, Mazurek S, Presek P, Friis RR (1994) Carbohydrate metabolism and neoplasia: New perspectives for diagnosis and therapy. In: Pretlow TG, Pretlow TP (eds) Biochemical and molecular aspects of selected cancers. Academic, San Diego, CA, pp 311–385

    Google Scholar 

  • Eigenbrodt E, Glossmann H (1980) Glycolysis—one of the keys to cancer ? Trends Pharmacol Sci 1:240–245

    CAS  Google Scholar 

  • Eigenbrodt E, Mazurek S, Friis RR, Eigenbrodt E, Mazurek S, Friis RR (1998) Double role of pyruvate kinase type M2 in the regulation of phosphometabolite pools. In: Bannasch P, Kanduc D, Papa S, Tager JM (eds) Cell growth and oncogenesis. Birkhäuser Verlag, Basel, pp 15–30

    Google Scholar 

  • Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H, Friis R (1992) Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit Rev Oncog 3:91–115

    CAS  PubMed  Google Scholar 

  • Ferguson EC, Rathmell JC (2008) New roles for pyruvate kinase M2: working out the Warburg effect. Trends Biochem Sci 33:359–362

    PubMed Central  CAS  PubMed  Google Scholar 

  • Frezza C, Gottlieb E (2009) Mitochondria in cancer: not just innocent bystanders. Semin Cancer Biol 19:4–11

    CAS  PubMed  Google Scholar 

  • Funes JM, Quintero M, Henderson S, Martinez D, Qureshi U, Westwood C, Clements MO, Bourboulia D, Pedley RB, Moncada S, Boshoff C (2007) Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci USA 104:6223–6228

    PubMed Central  CAS  PubMed  Google Scholar 

  • Gao X, Wang H, Yang JJ, Liu X, Liu ZR (2012) Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell 45:598–609

    PubMed Central  CAS  PubMed  Google Scholar 

  • Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891–899

    CAS  PubMed  Google Scholar 

  • Guminska M, Ignacak J, Kedryna T, Stachurska MB (1997) Tumor-specific pyruvate kinase isoenzyme M2 involved in biochemical strategy of energy generation in neoplastic cells. Acta Biochim Pol 44:711–724

    CAS  PubMed  Google Scholar 

  • Guminska M, Stachurska MB, Ignacak J (1988) Pyruvate kinase isoenzymes in chromatin extracts of Ehrlich ascites tumour, Morris hepatoma 7777 and normal mouse and rat livers. Biochim Biophys Acta 966:207–213

    CAS  PubMed  Google Scholar 

  • Guo W, Zhang Y, Chen T, Wang Y, Xue J, Xiao W, Mo X, Lu Y (2011) Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model. J Cancer Res Clin Oncol 1:65–72

    CAS  Google Scholar 

  • Gupta V, Bamezai RN (2010) Human pyruvate kinase M2: a multifunctional protein. Protein Sci 19:2031–2044

    PubMed Central  CAS  PubMed  Google Scholar 

  • Gupta V, Kalaiarasan P, Faheem M, Singh N, Iqbal MA, Bamezai RN (2010) Dominant negative mutations affect oligomerization of human pyruvate kinase M2 isozyme and promote cellular growth and polyploidy. J Biol Chem 285:16864–16873

    PubMed Central  CAS  PubMed  Google Scholar 

  • Hacker HJ, Steinberg P, Bannasch P (1998) Pyruvate kinase isoenzyme shift from L-type to M2-type is a late event in hepatocarcinogenesis induced in rats by a choline-deficient/DL-ethionine-supplemented diet. Carcinogenesis 19:99–107

    CAS  PubMed  Google Scholar 

  • Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, Dong S, Lonial S, Wang X, Chen GZ, Xie J, Gu TL, Polakiewicz RD, Roesel JL, Boggon TJ, Khuri FR, Gilliland DG, Cantley LC, Kaufman J, Chen J (2009) Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal 2:ra73

    PubMed Central  PubMed  Google Scholar 

  • Hoshino A, Hirst JA, Fujii H (2007) Regulation of cell proliferation by interleukin-3-induced nuclear translocation of pyruvate kinase. J Biol Chem 282:17706–17711

    CAS  PubMed  Google Scholar 

  • Hugo F, Fischer G, Eigenbrodt E (1999) Quantitative detection of tumor M2-PK in serum and plasma. Anticancer Res 19:2753–2757

    CAS  PubMed  Google Scholar 

  • Hume DA, Weidemann MJ (1979) Role and regulation of glucose metabolism in proliferating cells. J Natl Cancer Inst 62:3–8

    CAS  PubMed  Google Scholar 

  • Husain Z, Huang Y, Seth P, Sukhatme VP (2013) Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J Immunol 191:1486–1495

    CAS  PubMed  Google Scholar 

  • Ignacak J, Stachurska MB (2003) The dual activity of pyruvate kinase type M2 from chromatin extracts of neoplastic cells. Comp Biochem Physiol B Biochem Mol Biol 134:425–433

    PubMed  Google Scholar 

  • Iqbal MA, Bamezai RN (2012) Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of rapamycin. PLoS One 7:e36764

    PubMed Central  CAS  PubMed  Google Scholar 

  • Iqbal MA, Siddiqui FA, Gupta V, Chattopadhyay S, Gopinath P, Kumar B, Manvati S, Chaman N, Bamezai RN (2013) Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2. Mol Cancer 12:72

    PubMed Central  CAS  PubMed  Google Scholar 

  • Jiang JK, Boxer MB, Vander Heiden MG, Shen M, Skoumbourdis AP, Southall N, Veith H, Leister W, Austin CP, Park HW, Inglese J, Cantley LC, Auld DS, Thomas CJ (2010) Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg Med Chem Lett 20:3387–3393

    PubMed Central  CAS  PubMed  Google Scholar 

  • Kanno H, Fujii H, Wei DC, Chan LC, Hirono A, Tsukimoto I, Miwa S (1997) Frame shift mutation, exon skipping, and a two-codon deletion caused by splice site mutations account for pyruvate kinase deficiency. Blood 89:4213–4218

    CAS  PubMed  Google Scholar 

  • Kaura B, Bagga R, Patel FD (2004) Evaluation of the Pyruvate kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma. J Obstet Gynaecol Res 30:193–196

    CAS  PubMed  Google Scholar 

  • Kefas B, Comeau L, Erdle N, Montgomery E, Amos S, Purow B (2010) Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro Oncol 12:1102–1112

    PubMed Central  CAS  PubMed  Google Scholar 

  • Kumar Y, Tapuria N, Kirmani N, Davidson BR (2007) Tumour M2-pyruvate kinase: a gastrointestinal cancer marker. Eur J Gastroenterol Hepatol 19:265–276

    CAS  PubMed  Google Scholar 

  • Ladd JJ, Chao T, Johnson MM, Qiu J, Chin A, Israel R, Pitteri SJ, Mao J, Wu M, Amon LM, Mcintosh M, Li C, Prentice R, Disis N, Hanash S (2013) Autoantibody signatures involving glycolysis and spliceosome proteins precede a diagnosis of breast cancer among postmenopausal women. Cancer Res 73:1502–1513

    PubMed Central  CAS  PubMed  Google Scholar 

  • Larsen TM, Benning MM, Rayment I, Reed GH (1998) Structure of the bis(Mg2+)-ATP-oxalate complex of the rabbit muscle pyruvate kinase at 2.1 A resolution: ATP binding over a barrel. Biochemistry 37:6247–6255

    CAS  PubMed  Google Scholar 

  • Lee J, Kim HK, Han YM, Kim J (2008) Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int J Biochem Cell Biol 40:1043–1054

    CAS  PubMed  Google Scholar 

  • Lenzner C, Nurnberg P, Jacobasch G, Gerth C, Thiele BJ (1997) Molecular analysis of 29 pyruvate kinase-deficient patients from central Europe with hereditary hemolytic anemia. Blood 89:1793–1799

    CAS  PubMed  Google Scholar 

  • Luftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD, Possinger K (2000) Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 20:5077–5082

    CAS  PubMed  Google Scholar 

  • Lunt SY, Vander Heiden MG (2011) Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 27:441–464

    CAS  PubMed  Google Scholar 

  • Luo W, Hu H, Chang R, Zhong J, Knabel M, O’meally R, Cole RN, Pandey A, Semenza GL (2011) Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145:732–744

    PubMed Central  CAS  PubMed  Google Scholar 

  • Marchut E, Guminska M, Kedryna T (1986) The inhibitory effect of various fatty acids on aerobic glycolysis in Ehrlich ascites tumour cells. Acta Biochim Pol 33:7–16

    CAS  PubMed  Google Scholar 

  • Mazurek S (2007) Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours. Ernst Schering Found Symp Proc 4:99–124

    Google Scholar 

  • Mazurek S (2011) Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 43:969–980

    CAS  PubMed  Google Scholar 

  • Mazurek S, Boschek CB, Eigenbrodt E (1997) The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy. J Bioenerg Biomembr 29:315–330

    CAS  PubMed  Google Scholar 

  • Mazurek S, Boschek CB, Hugo F, Eigenbrodt E (2005) Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 15:300–308

    CAS  PubMed  Google Scholar 

  • Mazurek S, Drexler HC, Troppmair J, Eigenbrodt E, Rapp UR (2007) Regulation of pyruvate kinase type M2 by A-Raf: a possible glycolytic stop or go mechanism. Anticancer Res 27:3963–3971

    CAS  PubMed  Google Scholar 

  • Muellner S, Stark H, Niskanen P, Eigenbrodt E, Mazurek S, Fasold H (2006) From target to lead synthesis. In: Hamacher M, Marcus K, Stühler K, van Hall A, Warscheid B, Meyer HE (eds) Proteomics in drug research, vol 28. Wiley-VCH, Weinheim, pp 187–207

    Google Scholar 

  • Muirhead H (1990) Isoenzymes of pyruvate kinase. Biochem Soc Trans 18:193–196

    CAS  PubMed  Google Scholar 

  • Muirhead H, Clayden DA, Barford D, Lorimer CG, Fothergill-Gilmore LA, Schiltz E, Schmitt W (1986) The structure of cat muscle pyruvate kinase. EMBO J 5:475–481

    PubMed Central  CAS  PubMed  Google Scholar 

  • Niwa H, Miyazaki J, Smith AG (2000) Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 24:372–376

    CAS  PubMed  Google Scholar 

  • Noguchi T, Inoue H, Tanaka T (1986) The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J Biol Chem 261:13807–13812

    CAS  PubMed  Google Scholar 

  • Pfeiffer T, Schuster S, Bonhoeffer S (2001) Cooperation and competition in the evolution of ATP-producing pathways. Science 292:504–507

    CAS  PubMed  Google Scholar 

  • Pillai RS (2005) MicroRNA function: multiple mechanisms for a tiny RNA? RNA 11:1753–1761

    PubMed Central  CAS  PubMed  Google Scholar 

  • Pissard S, Max-Audit I, Skopinski L, Vasson A, Vivien P, Bimet C, Goossens M, Galacteros F, Wajcman H (2006) Pyruvate kinase deficiency in France: a 3-year study reveals 27 new mutations. Br J Haematol 133:683–689

    CAS  PubMed  Google Scholar 

  • Presek P, Reinacher M, Eigenbrodt E (1988) Pyruvate kinase type M2 is phosphorylated at tyrosine residues in cells transformed by Rous sarcoma virus. FEBS Lett 242:194–198

    CAS  PubMed  Google Scholar 

  • Reinacher M, Eigenbrodt E (1981) Immunohistological demonstration of the same type of pyruvate kinase isoenzyme (M2-Pk) in tumors of chicken and rat. Virchows Arch B Cell Pathol Incl Mol Pathol 37:79–88

    CAS  PubMed  Google Scholar 

  • Reinacher M, Eigenbrodt E, Schering B, Schoner W (1979) Immunohistochemical localization of pyruvate kinase isoenzymes in chicken tissues. Histochemistry 64:145–161

    CAS  PubMed  Google Scholar 

  • Robey IF, Martin NK (2011) Bicarbonate and dichloroacetate: evaluating pH altering therapies in a mouse model for metastatic breast cancer. BMC Cancer 11:235

    PubMed Central  CAS  PubMed  Google Scholar 

  • Rodriguez-Horche P, Luque J, Perez-Artes E, Pineda M, Pinilla M (1987) Comparative kinetic behaviour and regulation by fructose-1,6-bisphosphate and ATP of pyruvate kinase from erythrocytes, reticulocytes and bone marrow cells. Comp Biochem Physiol B 87:553–557

    CAS  PubMed  Google Scholar 

  • Satoh H, Tani K, Yoshida MC, Sasaki M, Miwa S, Fujii H (1988) The human liver-type pyruvate kinase (PKL) gene is on chromosome 1 at band q21. Cytogenet Cell Genet 47:132–133

    CAS  PubMed  Google Scholar 

  • Schafer D, Hamm-Kunzelmann B, Brand K (1997) Glucose regulates the promoter activity of aldolase A and pyruvate kinase M2 via dephosphorylation of Sp1. FEBS Lett 417:325–328

    CAS  PubMed  Google Scholar 

  • Schafer D, Hamm-Kunzelmann B, Hermfisse U, Brand K (1996) Differences in DNA-binding efficiency of Sp1 to aldolase and pyruvate kinase promoter correlate with altered redox states in resting and proliferating rat thymocytes. FEBS Lett 391:35–38

    CAS  PubMed  Google Scholar 

  • Schneider J, NEU K, Grimm H, Velcovsky HG, Weisse G, Eigenbrodt E (2002) Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res 22:311–318

    CAS  PubMed  Google Scholar 

  • SHI HS, LI D, Zhang J, Wang YS, Yang L, Zhang HL, Wang XH, Mu B, Wang W, Ma Y, Guo FC, Wei YQ (2010) Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. Cancer Sci 101:1447–1453

    CAS  PubMed  Google Scholar 

  • Shimada N, Shinagawa T, Ishii S (2008) Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML tumor suppressor protein. Genes Cells 13:245–254

    CAS  PubMed  Google Scholar 

  • Spoden GA, Mazurek S, Morandell D, Bacher N, Ausserlechner MJ, Jansen-Durr P, Eigenbrodt E, Zwerschke W (2008) Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation. Int J Cancer 123:312–321

    CAS  PubMed  Google Scholar 

  • Spoden GA, Rostek U, Lechner S, Mitterberger M, Mazurek S, Zwerschke W (2009) Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply. Exp Cell Res 315:2765–2774

    CAS  PubMed  Google Scholar 

  • Steinberg P, Klingelhoffer A, Schafer A, Wust G, Weisse G, Oesch F, Eigenbrodt E (1999) Expression of pyruvate kinase M2 in preneoplastic hepatic foci of N-nitrosomorpholine-treated rats. Virchows Arch 434:213–220

    CAS  PubMed  Google Scholar 

  • Stetak A, Veress R, Ovadi J, Csermely P, Keri G, Ullrich A (2007) Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res 67:1602–1608

    CAS  PubMed  Google Scholar 

  • Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, Wang Y, Jing Y, Yang H, Chen R, Chang L, Zhang Y, Goto J, Onda H, Chen T, Wang MR, Lu Y, You H, Kwiatkowski D, Zhang H (2011) Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA 108:4129–4134

    PubMed Central  CAS  PubMed  Google Scholar 

  • Tani K, Fujii H, Tsutsumi H, Sukegawa J, Toyoshima K, Yoshida MC, Noguchi T, Tanaka T, Miwa S (1987) Human liver type pyruvate kinase: cDNA cloning and chromosomal assignment. Biochem Biophys Res Commun 143:431–438

    CAS  PubMed  Google Scholar 

  • Thallion, Pharmaceutical & Inc. (Home page online). http://www.thallion.com/en/drug-development/tln-232.php

  • Tonus C, Sellinger M, Koss K, Neupert G (2012) Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis. World J Gastroenterol 18:4004–4011

    PubMed Central  CAS  PubMed  Google Scholar 

  • Ugurel S, Bell N, Sucker A, Zimpfer A, Rittgen W, Schadendorf D (2005) Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma. Int J Cancer 117:825–830

    CAS  PubMed  Google Scholar 

  • University, Medical, Centre & Utrecht (Home page online). http://www.pklrmutationdatabase.com/

  • Van Wijk R, Huizinga EG, Van Wesel AC, Van Oirschot BA, Hadders MA, Van Solinge WW (2009) Fifteen novel mutations in PKLR associated with pyruvate kinase (PK) deficiency: structural implications of amino acid substitutions in PK. Hum Mutat 30:446–453

    PubMed  Google Scholar 

  • Vander Heiden MG, Cantley LC, Thompson CB (2009a) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033

    Google Scholar 

  • Vander Heiden MG, Christofk HR, Schuman E, Subtelny AO, Sharfi H, Harlow EE, Xian J, Cantley LC (2009b) Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol 79:1118–1124

    PubMed Central  PubMed  Google Scholar 

  • Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D, Christofk HR, Wagner G, Rabinowitz JD, Asara JM, Cantley LC (2011) Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329:1492–1499

    Google Scholar 

  • Walsh MJ, Brimacombe KR, Veith H, Bougie JM, Daniel T, Leister W, Cantley LC, Israelsen WJ, Vander Heiden MG, Shen M, Auld DS, Thomas CJ, Boxer MB (2011) 2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg Med Chem Lett 21:6322–6327

    PubMed Central  CAS  PubMed  Google Scholar 

  • Wang C, Chiarelli LR, Bianchi P, Abraham DJ, Galizzi A, Mattevi A, Zanella A, Valentini G (2001) Human erythrocyte pyruvate kinase: characterization of the recombinant enzyme and a mutant form (R510Q) causing nonspherocytic hemolytic anemia. Blood 98:3113–3120

    CAS  PubMed  Google Scholar 

  • Warburg O (1956) On the origin of cancer cells. Science 123:309–314

    CAS  PubMed  Google Scholar 

  • Webb BA, Chimenti M, Jacobson MP, Barber DL (2011) Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer 11:671–677

    CAS  PubMed  Google Scholar 

  • Wechsel HW, Petri E, Bichler KH, Feil G (1999) Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res 19:2583–2590

    CAS  PubMed  Google Scholar 

  • Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR, Chandel NS (2010) Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 107:8788–8793

    PubMed Central  CAS  PubMed  Google Scholar 

  • Wong TS, Liu XB, Chung-Wai Ho A, Po-Wing Yuen A, Wai-Man NG, Ignace R, Wei W (2008) Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int J Cancer 123:251–257

    CAS  PubMed  Google Scholar 

  • Yamada K, Noguchi T (1999a) Nutrient and hormonal regulation of pyruvate kinase gene expression. Biochem J 337(Pt 1):1–11

    PubMed Central  CAS  PubMed  Google Scholar 

  • Yamada K, Noguchi T (1999b) Regulation of pyruvate kinase M gene expression. Biochem Biophys Res Commun 256:257–262

    CAS  PubMed  Google Scholar 

  • Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, Aldape K, Hunter T, Alfred Yung WK, Lu Z (2012a) PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 150:685–696

    PubMed Central  CAS  PubMed  Google Scholar 

  • Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, Gao X, Aldape K, Lu Z (2011) Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 480:118–122

    PubMed Central  CAS  PubMed  Google Scholar 

  • Yang W, Zheng Y, Xia Y, Ji H, Chen X, Guo F, Lyssiotis CA, Aldape K, Cantley LC, Lu Z (2012b) ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol 14:1295–1304

    PubMed Central  CAS  PubMed  Google Scholar 

  • Ye J, Mancuso A, Tong X, Ward PS, Fan J, Rabinowitz JD, Thompson CB (2012) Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc Natl Acad Sci USA 109:6904–6909

    PubMed Central  CAS  PubMed  Google Scholar 

  • Zhang Z, Liu Q, Che Y, Yuan X, Dai L, Zeng B, Jiao G, Zhang Y, Wu X, Yu Y, Yang R (2010) Antigen presentation by dendritic cells in tumors is disrupted by altered metabolism that involves pyruvate kinase M2 and its interaction with SOCS3. Cancer Res 70:89–98

    CAS  PubMed  Google Scholar 

  • Zwerschke W, Mazurek S, Massimi P, Banks L, Eigenbrodt E, Jansen-Durr P (1999) Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc Natl Acad Sci USA 96:1291–1296

    PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cancer Biology, Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA, 19104, USA

    Vibhor Gupta

  2. National Centre of Applied Human Genetics, School of Life Sciences, Jawaharlal Nehru University, New Delhi, 110067, India

    Vibhor Gupta, Mohd Askandar Iqbal, Bhupender Kumar & Rameshwar N. K. Bamezai

  3. Department of Clinical Cancer Prevention, MD Anderson Cancer Center, The University of Texas, Houston, TX, 77030, USA

    Mohd Askandar Iqbal

  4. SMVD University, Katra, Jammu, Jammu and Kashmir, India

    Rameshwar N. K. Bamezai

Authors
  1. Vibhor Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohd Askandar Iqbal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bhupender Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rameshwar N. K. Bamezai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rameshwar N. K. Bamezai .

Editor information

Editors and Affiliations

  1. Inst. of Veterinary Physiology and Bioch, Justus-Liebig-University of Giessen, Gießen, Hessen, Germany

    Sybille Mazurek

  2. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

    Maria Shoshan

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Wien

About this chapter

Cite this chapter

Gupta, V., Iqbal, M.A., Kumar, B., Bamezai, R.N.K. (2015). Pyruvate Kinase M2: A Metabolic Tuner. In: Mazurek, S., Shoshan, M. (eds) Tumor Cell Metabolism. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1824-5_6

Download citation

Publish with us

Policies and ethics

Search

Navigation